Bisker-Leib Vered
Known title: Chief Operating OfficerCIK: 0001814093
Associated companies
Transaction History
| CMPX | ▼ Sell | Tax Withholding | 49,198 | $71K | 2/8/2024 | View on chart |
| CMPX | ▲ Buy | Grant | 1,753,125 | $3.4M | 1/9/2024 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 64,415 | $97K | 11/17/2023 | View on chart |
| CMPX | ▲ Buy | Grant | 400,000 | $0 | 2/8/2023 | View on chart |
| CMPX | ▼ Sell | Open Market | 2 | $9 | 11/25/2022 | View on chart |
| CMPX | ▼ Sell | Open Market | 9,569 | $41K | 11/23/2022 | View on chart |
| CMPX | ▼ Sell | Open Market | 14,929 | $63K | 11/22/2022 | View on chart |
| CMPX | ▼ Sell | Open Market | 16,035 | $70K | 11/21/2022 | View on chart |
| CMPX | ▼ Sell | Open Market | 6,226 | $27K | 11/18/2022 | View on chart |
| CMPX | ▲ Buy | Grant | 600,000 | $0 | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback
Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.